

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED**

**中國神威藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2877)**

**2021 INTERIM RESULTS ANNOUNCEMENT**

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company” or “Shineway”) is pleased to present the unaudited consolidated results of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2021 (the “Period”) as follows:

**FINANCIAL HIGHLIGHTS**

For the six months ended 30 June 2021, the operating results of the Group were as follows:

- Turnover amounted to RMB1,554,097,000, an increase of 30.6% as compared to the corresponding period of last year;
- Gross profit margin was 73.8% as compared to 73.6% of the corresponding period of last year;
- Profit for the Period amounted to RMB308,456,000, an increase of 21.6% as compared to the corresponding period of last year;
- Earnings per share amounted to RMB41 cents, an increase of 24.2% as compared to the corresponding period of last year;
- Declared interim dividend of RMB39 cents per share;
- Net assets per share amounted to RMB7.2 (equivalent to HKD8.6); and
- Net cash per share amounted to RMB5.0 (equivalent to HKD6.0).

## **BUSINESS REVIEW**

### **Interim Results Highlights**

With the PRC government's great efforts on promoting the development of the traditional Chinese medicine ("TCM") sector accompanied by frequent introduction of relevant favorable policies and the gradually reducing impact of the COVID-19 pandemic in the first half of this year, the growth of the Group's business is recovering comprehensively. The Group's sales in the first six months of 2021 recorded an increase of 30.6% as compared with the same period last year. Net profit reached RMB308 million, representing a 21.6% growth from the same period last year, which was mainly attributable to the increase in sales. Net profit margin decreased from 21.3% in the same period last year to 19.8%, while earnings per share increased by 24.2% to RMB41 cents as compared to the same period last year.

The extent of increase in net profit was lower than that in sales, coupling with the decline in net profit margin. This was mainly due to the decrease of 42.2% in investment income and other income in the first half of this year as compared with the same period last year. Operating profit before taxation, as calculated by excluding investment income, other income, financial costs and taxes, amounted to RMB298,511,000 for the first six months of 2021, representing an increase of 74.4% as compared with RMB171,154,000 in the same period of last year.

The Group's gross profit margin was 73.8% for the first six-month period of 2021, representing a slight increase compared to 73.6% of the same period last year. This is mainly attributable to the continuous increase of proportion of profit contribution from oral products with higher gross profit margin.

As of 30 June 2021, the Group had bank deposits of RMB4,151,889,000 (equivalent to approximately HKD4,990,571,000) in total and there were no bank loans. As calculated based on the total issued shares of 827,000,000, net cash per share of the Group amounted to HKD6.0, and net assets per share amounted to HKD8.6. Interim dividend is set to be RMB39 cents per share to be paid out on 28 September 2021 to the shareholders whose names appear on the register of members of the Company on 16 September 2021.

The Group adopted a new dividend policy on 19 July 2021. For details, please refer to the announcement published by the Company on that day. The board of directors of the Group will review the new dividend policy when necessary to ensure its effectiveness and appropriateness.

## Growth Across the Board for All Dosage Forms

In the first half of 2021, the Group focused on positioning its key products with comprehensively enhanced end-to-end coverage and strengthened investment. Most key products achieved impressive sales growth, and injection products overall were restoring growth momentum during the Period. The table below shows the sales and growth rates of each dosage form for the first half of 2021 compared to the same period last year:

	Sales First six months of 2020 <i>RMB'000</i>	Sales First six months of 2021 <i>RMB'000</i>	Period-on- period growth rate	Percentage of sales First six months of 2021
Injection products	489,274	<b>635,382</b>	29.9%	40.9%
Soft capsule products	255,648	<b>275,126</b>	7.6%	17.7%
Granule products	147,312	<b>238,342</b>	61.8%	15.3%
TCM formula granules	239,762	<b>321,509</b>	34.1%	20.7%
Other product formats	<u>58,116</u>	<u><b>83,738</b></u>	<u>44.1%</u>	<u>5.4%</u>
Oral products	<u>700,838</u>	<u><b>918,715</b></u>	<u>31.1%</u>	<u>59.1%</u>
Total sales	<u><u>1,190,112</u></u>	<u><u><b>1,554,097</b></u></u>	<u><u>30.6%</u></u>	<u><u>100.0%</u></u>

Since the outbreak of COVID-19 pandemic, the PRC government has repeatedly emphasized the insistence on combining the use of traditional Chinese medicine and Western medications in the treatments. A number of Chinese medicine injections (including Shen Mai Injection, a medication produced by the Group) have also been included in the “Diagnosis and Treatment Program for Novel Coronavirus Infected Pneumonia (7th Trial Edition)”, highlighting the effectiveness and safety of Chinese medicine injections. While the market demand for Chinese medicine injections was gradually picking up, the Group had also proactively optimized its product mix of injection products, resulting in a 29.9% period-on-period increase in sales of injection products in the first half of this year.

The Group continued to focus on the development strategy of expanding new growth areas for oral products. The overall sales of oral products increased by 31.1% in the first half of 2021 as compared to the same period last year. In the first half of 2021, the sales of soft capsules, granules and TCM formula granules increased by 7.6%, 61.8% and 34.1% respectively as compared to the same period last year. The proportion of oral products sales reached 59.1% of the Group’s overall sales.

As estimated with internal data for the first six month period of 2021, oral products accounted for 74.1% of the Group’s gross profit after adjusting for the “Two-Invoices System” effect. The proportion of profit contribution from oral products was much higher than that of injection products. The following shows the estimated percentages of gross profit contribution after adjusting for the “Two-Invoices System” effect:

	<b>Percentage of gross profit contribution</b>	
	First six months of 2020	<b>First six months of 2021</b>
Injection products	27.7%	<b>25.9%</b>
Oral products	<u>72.3%</u>	<u><b>74.1%</b></u>
Total sales	100.0%	<b>100.0%</b>

Since our oral products had a higher overall gross profit margin than injection products, an increase in the proportion of sales of oral products would also enhance the Group’s profitability. The Group will continuously cultivate new growth areas to drive the growth momentum of oral products.

## Exclusive National Drugs Reimbursement List products grew rapidly

As at 30 June 2021, the Group possessed over 400 production permits on medications which consisted of more than 100 products regularly manufactured by the Group, covering 17 therapeutic areas. Among them there were 23 exclusive products of the Group and 18 products were admitted to the National Essential Drugs List. A total of 23 products were included in the National Low-Priced Medicine Catalogue, whereas 16 products were included in the Provincial Low-Priced Medicine Catalogue; and 3 products were included in the Catalogue of Emergency Use Drugs. Sales of the Group's key products in the first half of 2021 are respectively set out as follows:

			First six months of 2020 RMB'000	First six months of 2021 RMB'000	Year-on- year growth rate	Percentage of sales in the first six months of 2021
TCM formula granules	2 PDRL	-	239,762	<b>321,509</b>	34.1%	20.7%
Qing Kai Ling Injection	NDRL	Essential Drug	128,953	<b>145,053</b>	12.5%	9.3%
Guan Xin Ning Injection	NDRL	-	61,189	<b>142,464</b>	132.8%	9.2%
Shu Xie Ning Injection	NDRL	-	133,148	<b>130,639</b>	-1.9%	8.4%
Wu Fu Xin Nao Qing Soft Capsule	5 PDRL	-	96,837	<b>110,313</b>	13.9%	7.1%
Shen Mai Injection	NDRL	Essential Drug	81,633	<b>102,183</b>	25.2%	6.6%
Huamoyan Granule <sup>^</sup>	* NDRL	Essential Drug	36,803	<b>81,897</b>	122.5%	5.3%
Huo Xiang Zheng Qi Soft Capsule	NDRL	Essential Drug	93,568	<b>82,354</b>	-12.0%	5.3%
Dan Shen Injection	NDRL	Essential Drug	29,912	<b>47,232</b>	57.9%	3.0%
Pseudomonas Aeruginosa Injection <sup>^</sup>	9 PDRL	-	31,163	<b>43,426</b>	39.4%	2.8%
Pediatric Qingfei Huatan Granule	3 PDRL	-	23,904	<b>36,549</b>	52.9%	2.4%
Qing Kai Ling Soft Capsule <sup>^</sup>	NDRL	Essential Drug	32,063	<b>25,017</b>	-22.0%	1.6%
Qi Huang Tong Mi Soft Capsule <sup>^</sup>	* NDRL	-	5,537	<b>18,108</b>	227.0%	1.2%
Xiesaitong Dripping Pill	* NDRL	-	11,475	<b>17,184</b>	49.8%	1.1%
Dan Deng Tong Nao Soft Capsule <sup>^</sup>	# NDRL	-	2,716	<b>6,637</b>	144.4%	0.4%
Others			181,449	<b>243,532</b>	34.2%	15.6%
Total sales			<u>1,190,112</u>	<u><b>1,554,097</b></u>	<u>30.6%</u>	<u>100.0%</u>

<sup>^</sup> The Group's exclusive products

\* Newly included in the 2019 edition of National Drugs Reimbursement List

# Newly included in the 2020 edition of National Drugs Reimbursement List

The sales of a number of National Drugs Reimbursement List exclusive products grew rapidly. In particular, the sales of Huamoyan Granule, Qi Huang Tong Mi Soft Capsule, Xiesaitong Dripping Pill and Dan Deng Tong Nao Soft Capsule increased by 122.5%, 227.0%, 49.8% and 144.4% respectively during the first six months of this year as compared to the same period last year. Huamoyan Granule is an exclusive innovative medication of the Group and is the only innovative Chinese medicine for treating knee joint synovitis approved by the National Medical Products Administration, filling the gap in both Western medications and traditional Chinese medicine in the treatment of synovitis in China. Qi Huang Tong Mi Soft Capsule and Dan Deng Tong Nao Soft Capsule are under the National Drugs Reimbursement Negotiation List which permits direct listing on the provincial centralized online drug procurement platforms and are not subject to the restrictions on drug usage proportion, reimbursement cap and the quota of usage in medical institutions. These products are expected to continuously achieve excellent sales performance.

## **PRC continued to issue polices and measures boosting the development of TCM**

During the first six months of 2021, the PRC government continued to issue a number of policy documents to promote the revitalization and development of traditional Chinese medicine. Following the release of “Several Policies on Accelerating the Characteristic Development of Traditional Chinese Medicines” by the General Office of the State Council in February this year, the National Health Commission, State Administration of Traditional Chinese Medicine and the Health Bureau of Logistics Support Department of Central Military Commission jointly issued the “Opinions on Further Enhancing the Work of Traditional Chinese Medicine in General Hospitals to Promote the Synergistic Development of Traditional Chinese Medicine and Western Medicine” in June this year, with an aim to intensify traditional Chinese medicine in general hospitals by strengthening clinical facilities of Chinese medicine and encouraging the establishment of secondary disciplines or specialized groups of traditional Chinese medicine, and to promote the synergistic development of Chinese and Western medicine with an improved synergistic system.

On 1 July 2021, four ministries including the National Development and Reform Commission jointly issued the “Implementation Plan to Establish A High-quality and Efficient Medical and Health Service System during the Fourteenth Five-Years”, which proposes to establish about 30 national inheritance and innovation centers for traditional Chinese medicine by 2025, with focus on improving the capabilities of basic research on traditional Chinese medicine, diagnosis and treatment of dominant diseases, cultivation of high-level talents, research and development of equipment and new medications for traditional Chinese medicine and transformation of scientific and technological achievements.

On 7 July 2021, five government agencies including the State Administration of Traditional Chinese Medicine and the Publicity Department of the Central Committee jointly issued the “Implementation Plan to Spread the Culture of Traditional Chinese Medicine (2021-2025)” with an aim to carry out the cultural transmission of traditional Chinese medicine by promoting traditional Chinese medicine at work and daily life, establishing a traditional Chinese medical culture dissemination mechanism and integrating the culture of traditional Chinese medicine throughout national education, rendering it the cultural consciousness of the public to promote health.

To capture the opportunities arisen from these favourable policies for the development of traditional Chinese medicine, the Group is keeping on its efforts and continuing to increase its investment, so as to build up a new development cycle in the future and promote rapid business expansion.

### **Formula granules to be sold nationwide**

TCM formula granules, being the Group’s product with the largest sales revenue, continued to show a rapid growth trend during the first six months of 2021, with an increase in sales of 34.1% as compared to the same period last year. Most of the sales volume continued to be originated from Hebei Province. The Group’s full efforts in exploiting the Yunnan market has begun this year resulting in sales of more than RMB12 million in the first half of the year, making progress similar to the early days of cultivating the Hebei Province market by the Group. The work on penetrating medical institutions in Yunnan province is underway with every effort to achieve sales target for the year.

In February 2021, four ministries including the National Medical Product Administration jointly issued the “Announcement on Ending the Pilot Trial on TCM Formula Granules”, which has brought about the opening up of the nationwide TCM formula granule market by officially allowing manufacturers to sell TCM formula granules across provinces after registering with the respective local provincial drug regulatory authorities upon the effective date of 1 November 2021.

The Group is currently in the process of expanding the production capacity of TCM formula granules to an annual production value of RMB4 billion. It is expected to be completed by the end of this year so that the Group will be well positioned for its TCM formula granules to tap into the nationwide markets.

Meanwhile, the Group has been making the relevant arrangements necessary to enter into various provincial markets, including the expansion of sales teams in preparation for the promotion of the Group’s TCM formula granules to local hospitals and primary medical institutions immediately upon successful registration in these provinces and cities. The goal is to become one of the leading suppliers of TCM formula granules in the PRC by 2024.

The PRC government is currently carrying out the discussion on the procurement of traditional Chinese medicine under a centralized platform. Hainan Province has also recently issued the notice for the “Management Measures for TCM formula granules of Hainan Province (For Trial Implementation)”, which stipulated the setting up of a TCM formula granules segment on the provincial centralised drug procurement platform, and formulated and published the corresponding rules for tendering. TCM formula granules used by public medical institutions shall be procured online through the provincial centralised drug procurement platform, while prohibiting offline purchase. Products of manufacturers that have not been registered at the relevant provincial regulatory agency may not be procured. Recently, the National Healthcare Security Administration via the “Response of the National Healthcare Security Administration to Recommendation No. 4126 of the Fourth Session of the 13th National People’s Congress” stated that in the next step, it will work with relevant departments to improve the quality evaluation standards of traditional Chinese medicines and TCM formula granules by adhering to the clinical demand-oriented principle of quality first for high-priced and large-volume varieties, and scientifically and steadily promote the reform of centralized procurement of traditional Chinese medicine and TCM formula granules. The Group considers that if TCM formula granules across provinces in the PRC are to be procured through centralized province-level online platforms in the future, it is likely to be an opportunity to penetrate into the nationwide markets at a faster pace. Suppliers of TCM formula granules with limited varieties or failing to meet the national uniform standards will not be able to participate in such procurements, while those with the full range of products which are of high quality and meet the national uniform standards will make their presence in the market of online procurement platforms in various provinces.

## **Exclusive products are becoming a new force for growth**

In the first six months of 2021, the sales of the Group's exclusive traditional Chinese medicine products with proprietary intellectual property rights increased to a greater extent. A total of 22 relevant exclusive traditional Chinese medicine had recorded sales of RMB170,571,000 in aggregate, representing an increase of 82.0% over the same period last year and accounting for 11.0% of the Group's total sales. In particular, Huamoyan Granule recorded sales of RMB81,897,000, an increase of 122.5% as compared to the same period last year; Qi Huang Tong Mi Soft Capsule recorded sales of RMB18,108,000, an increase of 227.0% as compared to the same period last year; and Qing Kai Ling Soft Capsule recorded a period-on-period decrease in sales for the first six months of this year by 22.0% due to the relatively larger comparable base in the same period last year caused by the COVID-19 epidemic, with sales amounted to RMB25,017,000 only.

Promotion of Xiao Jie An Capsule, the Group's exclusive oral gynecological traditional Chinese medicine product on National Drug Reimbursement List and Xiao Jie An Oral Liquid under the same series, had commenced in the first quarter of this year. They had recorded a total sales of RMB5,425,000 during the Period and became new elements to the Group's exclusive product mix.

The Group is speeding up on its evidence-based medical researches of its exclusive oral products of traditional Chinese medicine used in six core therapeutic areas, being orthopedics, cardio-cerebrovascular diseases, anti-viral, gastroenterology, gynecology and pediatrics. Such evidence-based medical researches are being conducted through expert argumentation and other methods. As academic promotion has become the Group's key initiative, the Group will continue to utilize medical evidence-based strategies to develop the Group's exclusive oral products to be the forthcoming new driving force for our growth.

## **Online sales surged by 280.4%**

The Internet digital marketing team of the Group achieved online sales of approximately RMB79 million in the first half of 2021, representing an increase of 280.4% over the same period last year. Sales through B2B third-party online platforms accounted for 79.3% of total online revenue, and sales through B2C online e-commerce platforms accounted for about 20.7%.

The Group continued to actively collaborate with various B2B third-party online pharmaceutical platforms to promote mainly the distribution of our oral products to terminal customers. Catering to the difference of online pharmaceutical market characteristics in various provinces and regions, the Group has established presence in the B2B online market through serving different types of customers. In the first half of this year, the Group sold to 22,000 additional terminal customers online, with a total of 71,260 terminal customers being covered online currently. Meanwhile, under the B2C model, the Group continued to strengthen the cooperation with leading pharmaceutical e-commerce platforms where our online sales were growing at the fastest pace, including JD Pharmacy, ehaoyao.com, 111.com and Ali Pharmacy. In addition, the Group has also embarked on exploring Internet hospital customers and initiating the cooperation with O2O offline shops of major e-commerce platforms. Concurrently, the Group has also put more efforts in marketing via Internet media to further increase the sales of our relevant products.



Online sales of pharmaceutical products and online hospitals are still at the early stage of development with huge growth potential. The Group regards online sales as one of its key strategic development areas. Currently, it is stepping up the efforts to expand its online marketing team and online sales platform, striving to build its core competitiveness in online marketing.

### **Accelerating the development of exclusive innovative medications**

The Group focused on the research and development of innovative medications with clinical advantages and unique characteristics, and adopted the combined strategy of independent and joint research and development, and patents trading to accelerate the development of new core product pipelines. The Group currently has a total of 3 groundbreaking exclusive medications undergoing clinical trials:

#### **1. *Sailuotong Capsule***

The Group's key research initiative "Sailuotong Capsule", an innovative compound TCM, is now under phase III clinical trials in China and Australia. The phase III clinical trial in China mainly addresses the treatment of vascular dementia, while the phase III clinical trial in Australia focuses on the treatment of vascular dementia and Alzheimer's disease.

Sailuotong Capsule is composed of the effective parts of three traditional Chinese medicine herbs, namely ginkgo biloba, ginseng and saffron. Through scientific research, effective components that improve the cognition and daily functioning of patients with mild to moderate dementia are extracted from each herb. With clear chemical composition, precise mechanism of action and full proprietary intellectual property rights, Sailuotong Capsule has filled the gap in the therapeutic field of vascular dementia. According to medical data, there is currently no registered drug for treatment of vascular dementia. The findings from the Phase II clinical trial of Sailuotong indicated that it might be safe and effective in the treatment of mild to moderate vascular dementia.

In December 2020, an international medical journal "The Lancet Public Health" published a research report online on the dementia among people over 60 years old in China. The journal revealed that there were 15.07 million patients with dementia among the people of 60 years old or above in China, including 9.83 million patients with Alzheimer's disease, 3.92 million patients with vascular dementia and 1.32 million patients with other dementia. In September 2020, a research report from the World Health Organization also pointed out that more than 50 million people worldwide were suffering from dementia, with an increase of 10 million new cases each year. Once Sailuotong Capsule is introduced to the market, it will provide an effective and safe alternative for treating large number of patients with dementia.

In early 2019, Sailuotong Capsule was granted an invention patent by IP Australia, and also received a notice of patent family grant from Russia in the same month. Since the first overseas invention patent granted in 2010, Sailuotong Capsule has been granted 8 invention patents by countries including the United States, Japan, Korea, Germany, Russia, Canada and Australia etc.

## 2. *Q-B-Q-F Condensed Pill*

Q-B-Q-F Condensed Pill focuses on the treatment of mycoplasma pneumonia in children and is currently undergoing phase III clinical trial. Further details of Q-B-Q-F Condensed Pill are disclosed in the Company's 2019 interim report.

## 3. *JC Soft Capsule*

JC Soft Capsule is a compound TCM developed under the guidelines based on the traditional medicine theory. It is a new medication of compounded Chinese medicine using "detoxification from the interior to exterior" as the principle for treatment of common cold. It is used for treating upper respiratory infection with symptoms such as fever and aversion to cold, dry and sore throat, nasal congestion and runny nose, headache and cough, etc. At present, most traditional Chinese medicines in the market for treating common cold are heat-clearing detoxifying types and antiseptics, but none of those in the market are available for "detoxification from the interior to exterior". JC Soft Capsule is currently undergoing phase III clinical trial.

## **FINANCIAL ANALYSIS**

### **Turnover**

For the first six months of 2021, the Group continued to produce modern Chinese medicine products of good efficacy and high quality. The Group's turnover had increased by 30.6% as compared to the corresponding period of last year. Sales of our injection products had increased by 29.9% to RMB635,382,000, accounted for 40.9% of the Group's total turnover. Sales of soft capsule products had increased by 7.6% to RMB275,126,000, accounted for 17.7% of the Group's total turnover. Sales of granule products had increased by 61.8% to RMB238,342,000, accounted for 15.3% of the Group's total turnover. Sales of TCM formula granules had increased by 34.1% to RMB321,509,000, accounted for 20.7% of the Group's total turnover. The Group had also sold RMB83,738,000 of medicines in other formats which accounted for 5.4% of the Group's turnover.

Sales of prescription and OTC medicines of the Group for the first six months of 2021 were RMB1,344,257,000 and RMB209,840,000 respectively, which equal to 86.5% and 13.5% of the Group's turnover respectively.

### **Cost of Sales**

Cost of sales of the Group for the first six months of 2021 was RMB407,067,000, which equals to 26.2% of the Group's turnover. Direct materials, direct labour and other production costs accounted for 63.7%, 14.2% and 22.1% of the total production costs respectively (for the corresponding period of 2020: 57.6%, 16.7% and 25.7%).

## **Gross Profit Margin**

For the first six months of 2021, average gross margin of the Group's injection products, soft capsule products, granule products and TCM formula granule products were approximately 77.4% (for the corresponding period of 2020: 75.6%), 75.1% (for the corresponding period of 2020: 75.3%), 76.5% (for the corresponding period of 2020: 70.0%) and 69.3% (for the corresponding period of 2020: 73.2%) respectively. Overall gross profit margin was 73.8% as compared to 73.6% of the corresponding period of last year.

## **Other Income**

Other income mainly includes government subsidies of RMB24,881,000 (for the corresponding period of 2020: RMB67,370,000). The government subsidies mainly represented incentives received from the government for research activities and investments in the relevant regions in the PRC by the Group and recognition of deferred income in relation to disposal of property, plant and equipment due to land resumption by the local government.

## **Investment Income**

Investment income mainly includes interest income from bank deposits and investments in financial products of RMB47,119,000 (for the corresponding period of 2020: RMB51,256,000) and RMB3,903,000 (for the corresponding period of 2020: RMB19,021,000) respectively.

## **Other gains and losses**

Other gains and losses comprised of net exchange gain and loss on disposal of property, plant and equipment. The Group recorded net exchange gain of RMB518,000 for the first six months of 2021 (for the corresponding period of 2020: net exchange gain of RMB3,822,000), which was mainly resulted from exchange gain arising from change of exchange rate among Australian dollars, Hong Kong dollars and Renminbi. Besides, the net loss on disposal of property, plant and equipment for this period was RMB8,237,000 (for the corresponding period of 2020: net gain of RMB2,950,000).

## **Selling and Distribution Costs**

Selling and distribution costs for the first six months of 2021 increased by 25.0% from the corresponding period of last year and were equal to 45.2% of the Group's turnover (for the corresponding period of 2020: 47.2%). The increase was mainly due to the increase in advertising expense, market development expense and sale management expense as compared to same period of last year.

## **Administrative Expenses**

As a result of the Group strengthened cost control coupled with the effect of reduced amortisation expenses of intangible assets in the first six months of 2021, administrative expenses decreased by 10.7% as compared to the corresponding period of last year, representing approximately 7.3% (for the corresponding period of 2020: 10.6%) of the Group's turnover. Administrative expenses mainly comprised of salaries and social security outlay of administration staff, depreciation expenses of property, plant and equipment and amortisation expenses of intangible assets which accounted for 2.3% and 1.5% (for the corresponding period of 2020: 3.4% and 3.4%) of the Group's turnover respectively.

## **Research and Development Costs**

During the first six months of 2021, research and development costs accounted for approximately 1.6% of the Group's turnover (for the corresponding period of 2020: 1.7%) which was comparable with the corresponding period of last year.

## **Taxation**

Taxation for the first six months ended 30 June 2021 amounted to RMB71,966,000 (for the corresponding period of 2020: RMB48,088,000). The effective tax rate was increased from 15.9% in the corresponding period of last year to 18.9%. This was mainly due to the under provision of tax in prior years and the withholding tax related to dividend distributions of subsidiaries in the Mainland China during the period.

## **Profit for the Period**

The Group's net profit for the first six months ended 30 June 2021 was RMB308,456,000 representing an increase of 21.6% as compared to the corresponding period of last year. The rise in profit was mainly attributable to the increased turnover and operating profit during the period.

## **Liquidity and Financial Resources**

As at 30 June 2021, bank deposits of the Group amounted to RMB4,151,889,000 (31 December 2020: RMB3,943,010,000) of which RMB3,990,343,000 (31 December 2020: RMB3,800,912,000), were denominated in Renminbi. Others being equivalent to RMB136,537,000, RMB21,698,000 and RMB3,311,000 (31 December 2020: RMB92,627,000, RMB46,143,000 and RMB3,328,000) were denominated in Hong Kong dollars, Australian dollars and United States dollars respectively.

The directors of the Company believe that the financial position of the Group is healthy, with sufficient financial resources to meet the need for future development.

## **Property, Plant and Equipment**

In the first six months of 2021, the Group acquired buildings of RMB1,035,000, plant and machinery of RMB16,061,000, office equipment of RMB6,201,000 and the addition to construction in progress amounted to approximately RMB3,724,000 in total. Besides, following the adoption of IFRS 16, property, plant and equipment had included the leasehold land, leasehold properties, leasehold motor vehicles and leasehold machineries which had respective net book values of RMB118,586,000, RMB4,410,000, RMB2,966,000 and RMB4,851,000 as at 30 June 2021.

For the six months ended 30 June 2021, depreciation for property, plant and equipment amounted to RMB83,655,000 as compared to RMB82,779,000 during the same period of last year.

## **Acquisition of a subsidiary**

In February 2021, the Group entered into a sales and purchase agreement with an independent third party to acquire the entire interest of Shineway Pharmaceutical (Kunming) Company Limited (formerly known as Yunnan Liangfang Pharmaceutical Co., Ltd) at a cash consideration of RMB137,140,000 (“the Acquisition”). Goodwill and intangible assets with finite lives generated from the Acquisition were RMB63,459,000 and RMB44,683,000 respectively. Shineway Pharmaceutical (Kunming) Company Limited was incorporated in the PRC with principal activities in manufacturing and trading of Chinese pharmaceutical products.

## **Interim Dividend**

The Board resolved to declare an interim dividend of RMB39 cents per share amounting to RMB294,606,000 in respect of the six months ended 30 June 2021 and are calculated on the basis of 827,000,000 shares issued less 71,600,000 shares held for share award scheme as at 30 June 2021 (for the six months ended 30 June 2020: RMB11 cents per share, amounting to RMB83,006,000), which will be paid on 28 September 2021 to the shareholders whose names appear on the Company’s register of members on 16 September 2021.

The above interim dividend will be payable in cash in Hong Kong dollars and will be converted from Renminbi at the telegraphic transfer exchange rates quoted by bank at 10:00 a.m. on 31 August 2021 (RMB1=HK\$1.204). Accordingly, the amount payable on 28 September 2021 will be HK\$0.4696 per share.

## INTERIM RESULTS

The unaudited consolidated results of the Group for the six months ended 30 June 2021 together with the comparative figures for the six months ended 30 June 2020 are as follows:

### CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2021

	NOTES	Six months ended 30 June	
		2021 RMB'000 (Unaudited)	2020 RMB'000 (Unaudited)
Revenue	3	1,554,097	1,190,112
Cost of sales		<u>(407,067)</u>	<u>(313,747)</u>
Gross profit		1,147,030	876,365
Other income		32,119	73,732
Investment income		51,090	70,277
Other gains and losses		(7,719)	6,772
Impairment losses on financial assets under expected credit loss model, net of reversal	10	(525)	(3,487)
Selling and distribution costs		(702,236)	(561,832)
Administrative expenses		(113,014)	(126,488)
Research and development costs		(25,025)	(20,176)
Finance costs		<u>(1,298)</u>	<u>(13,354)</u>
Profit before taxation		380,422	301,809
Taxation	4	<u>(71,966)</u>	<u>(48,088)</u>
Profit and total comprehensive income for the period	5	<u><u>308,456</u></u>	<u><u>253,721</u></u>
Earnings per share	7		
Basic		<u><u>RMB41 cents</u></u>	<u><u>RMB33 cents</u></u>
Diluted		<u><u>RMB41 cents</u></u>	<u><u>RMB33 cents</u></u>

## CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2021

	<i>NOTES</i>	<b>30.6.2021</b> <b>RMB'000</b> <b>(Unaudited)</b>	31.12.2020 <b>RMB'000</b> <b>(Audited)</b>
Non-current assets			
Property, plant and equipment	8	<b>1,304,453</b>	1,394,771
Intangible assets		<b>75,966</b>	36,959
Goodwill		<b>165,956</b>	102,497
Deposit for acquisition of a subsidiary		–	137,140
Deferred tax assets		<b>19,417</b>	23,104
		<u><b>1,565,792</b></u>	<u>1,694,471</u>
Current assets			
Inventories		<b>434,078</b>	442,999
Trade receivables	9	<b>401,237</b>	311,792
Trade receivables backed by bank bills	9	<b>370,573</b>	448,868
Prepayments, deposits and other receivables		<b>87,347</b>	72,320
Tax recoverable		–	48
Financial assets at fair value through profit or loss		<b>22,621</b>	–
Pledged bank deposits		–	300,000
Bank balances and cash		<b>4,151,889</b>	3,943,010
		<u><b>5,467,745</b></u>	<u>5,519,037</u>
Current liabilities			
Trade payables	11	<b>146,033</b>	164,377
Other payables and accrued expenses		<b>588,038</b>	501,628
Bank borrowings	12	–	369,319
Lease liabilities		<b>7,975</b>	7,791
Contract liabilities		<b>59,762</b>	67,672
Amounts due to related companies		<b>13,784</b>	14,784
Deferred income		<b>22,204</b>	10,749
Tax payable		<b>41,243</b>	58,372
		<u><b>879,039</b></u>	<u>1,194,692</u>
Net current assets		<u><b>4,588,706</b></u>	<u>4,324,345</u>
Total assets less current liabilities		<u><b>6,154,498</b></u>	<u>6,018,816</u>

	<b>30.6.2021</b>	31.12.2020
	<b><i>RMB'000</i></b>	<i>RMB'000</i>
	<b>(Unaudited)</b>	(Audited)
Non-current liabilities		
Lease liabilities	<b>10,983</b>	15,028
Deferred tax liabilities	<b>18,109</b>	5,297
Deferred income	<b>177,537</b>	204,309
	<b>206,629</b>	224,634
Net assets	<b>5,947,869</b>	5,794,182
Capital and reserves		
Share capital	<b>87,662</b>	87,662
Reserves	<b>5,860,207</b>	5,706,520
Total equity	<b>5,947,869</b>	5,794,182



# NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

*For the six months ended 30 June 2021*

## 1. GENERAL

The condensed consolidated financial statements have been prepared in accordance with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and International Accounting Standard 34 “Interim Financial Reporting” issued by International Accounting Standards Board.

The Group’s condensed consolidated financial statements are presented in Renminbi (“RMB”) which is also the functional currency of the Company.

## 2. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values, as appropriate.

The accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2021 are the same as those presented in the preparation of the Group’s annual financial statements for the year ended 31 December 2020.

### **Application of amendments to International Financial Reporting Standards (“IFRS Standards”)**

In the current interim period, the Group has applied the following amendments to IFRS Standards, for the first time, which are mandatorily effective for the annual periods beginning on or after 1 January 2021 for the preparation of the Group’s condensed consolidated financial statements:

Amendment to IFRS 16	Covid-19-Related Rent Concessions
Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16	Interest Rate Benchmark Reform – Phase 2

The application of the amendments to IFRS Standards in the current interim period has had no material impact on the Group’s financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

### 3. REVENUE AND SEGMENT INFORMATION

#### Operating segment

The Group is engaged in a single operating segment in research and development, manufacturing and trading of Chinese pharmaceutical products. This operating segment has been identified on the basis of internal management reports that are regularly reviewed by the Chairman of the Board of Directors of the Group, being the chief operating decision maker, for the purpose of resources allocation and performance assessment. No other discrete financial information is provided other than the Group's results and financial position as a whole.

#### Revenue from major products

The following is an analysis of the Group's revenue from its major products:

	Six months ended 30 June	
	2021 <i>RMB'000</i> (Unaudited)	2020 <i>RMB'000</i> (Unaudited)
Injections	635,382	489,274
Soft capsules	275,126	255,648
Granules	238,342	147,312
Traditional Chinese medicine formula granules	321,509	239,762
Others	83,738	58,116
	<u>1,554,097</u>	<u>1,190,112</u>

Sales of the Group to external customers were substantially made in the PRC including Hong Kong.

#### 4. TAXATION

	Six months ended 30 June	
	2021 <i>RMB'000</i> (Unaudited)	2020 <i>RMB'000</i> (Unaudited)
PRC Enterprise Income Tax (“EIT”):		
Current tax	60,180	53,420
Under (over) provision in prior years	3,326	(4,705)
	63,506	48,715
Deferred tax	8,460	(627)
	71,966	48,088

On 21 March 2018, the Hong Kong Legislative Council passed The Inland Revenue (Amendment) (No. 7) Bill 2017 (the “Bill”) which introduces the two-tiered profits tax rates regime. The Bill was signed into law on 28 March 2018 and was gazetted on the following day. Under the two-tiered profits tax rates regime, the first HK\$2 million of profits of the qualifying group entity will be taxed at 8.25%, and profits above HK\$2 million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%. As the Company and its subsidiaries operating in Hong Kong do not have assessable profits, no provision for Hong Kong Profits Tax has been made in the condensed consolidated financial statements.

Under the Law of the PRC on EIT (the “EIT Law”) and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% for both periods.

A subsidiary which is operating in Western China has been granted tax concession by the local tax bureau and is entitled to PRC EIT at concessionary rate of 15% for both periods. Certain subsidiaries which are recognised as High and New-tech Enterprises have been granted tax concessions by the local tax bureau and are entitled to PRC EIT at concessionary rate of 15% for both periods.

According to a joint circular of the Ministry of Finance and State Administration of Taxation, Cai Shui 2011 No. 1, only the profits earned by foreign-investment enterprise prior to 1 January 2008, when distributed to foreign investors, can be grandfathered and exempted from withholding tax. Whereas, dividend distributed out of the profits generated thereafter shall be subject to the Enterprise Income Tax at 5% or 10% and withheld by the PRC entities, pursuant to Articles 3 and 27 of the New Tax Law and Article 91 of its Detailed Implementation Rules.

Under the applicable corporate tax law in Australia, income tax is charged at 27.5% (six months ended 30 June 2020: 27.5%) of the estimated assessable profits. No provision for Australian income tax has been made in the condensed consolidated financial statements as the subsidiary operating in Australia has no assessable profits for both periods.

Under the EIT Law, withholding tax is imposed on dividends declared in respect of profits earned by PRC subsidiaries from 1 January 2008 onwards. Deferred taxation has not been provided for in the condensed consolidated financial statements in respect of temporary differences attributable to accumulated undistributed profits of the PRC subsidiaries amounting to RMB5,084,988,000 (31 December 2020: RMB4,818,796,000) as the Group is able to control the timing of the reversal of the temporary differences and it is probable that the temporary differences will not be reversed in the foreseeable future.

## 5. PROFIT FOR THE PERIOD

	<b>Six months ended 30 June</b>	
	<b>2021</b>	<b>2020</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Profit for the period has been arrived at after charging (crediting):		
Amortisation of intangible assets	<b>5,676</b>	21,315
Depreciation of property, plant and equipment	<b>83,655</b>	82,779
Government subsidies (included in other income) ( <i>Note</i> )	<b>(24,881)</b>	(67,370)
Net exchange gain (included in other gains and losses)	<b>(518)</b>	(3,822)
Loss (gain) on disposal of property, plant and equipment (included in other gains and losses)	<b>8,237</b>	(2,950)
Share-based payments expense	<b>34</b>	95
	<b>34</b>	95

*Note:* The government subsidies represented the amounts received from the local government by the subsidiaries of the Company. During the six months ended 30 June 2021, government subsidies of (a) RMB3,371,000 (six months ended 30 June 2020: RMB59,808,000) represented incentives received in relation to engagement of the subsidiaries of the Company in high technology business. The grants were unconditional, approved and received during the year of recognition; (b) RMB6,456,000 (six months ended 30 June 2020: RMB7,562,000) represented recognition of deferred income upon completion of related research activities and development projects; and (c) RMB15,054,000 (six months ended 30 June 2020: nil) represented recognition of deferred income in relation to disposal of property, plant and equipment in 邛崃醫藥產業園 (Qionglai Pharmaceutical Area) in Sichuan Province in the PRC due to a land resumption by local government, which associated with a government grant received in 2011. .

## 6. DIVIDENDS

	Six months ended 30 June	
	2021 <i>RMB'000</i> (Unaudited)	2020 <i>RMB'000</i> (Unaudited)
Dividends		
– 2020 final dividend of RMB21 cents (2020: 2019 final dividend of RMB12 cents) per share paid	158,466	90,552
– 2021: 2020 special dividend of nil (2020: 2019 special dividend of RMB9 cents per share paid)	–	67,914
	<u>158,466</u>	<u>158,466</u>
– 2021 interim dividend of RMB39 cents (2020: RMB11 cents) per share	<u>294,606</u>	<u>83,006</u>

The interim dividend of RMB39 cents (six months ended 30 June 2020: RMB11 cents) per share which was proposed by the directors of the Company for the period has been calculated on the basis of 827,000,000 (30 June 2020: 827,000,000) shares in issue less 71,600,000 (30 June 2020: 72,400,000) shares held for share award scheme as at 30 June 2021, and will be paid on 28 September 2021, to the shareholders of the Company whose names appear in the Company's register of members on 16 September 2021.

## 7. EARNINGS PER SHARE

The calculation of basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

	Six months ended 30 June	
	2021 <i>RMB'000</i> (Unaudited)	2020 <i>RMB'000</i> (Unaudited)
Profit for the period attributable to the owners of the Company for the purpose of basic and diluted earnings per share	<u>308,456</u>	<u>253,721</u>
Six months ended 30 June		
	2021	2020
Weighted average number of ordinary shares in issue less shares held for share award scheme for the purpose of calculation of basic and diluted earnings per share	<u>754,877,901</u>	<u>758,879,401</u>

The computation of diluted earnings per share does not assume the exercise of the Company's options at exercise prices of HK\$8.39 and HK\$7.21 (six months ended 30 June 2020: HK\$8.39 and HK\$7.21) because the exercise prices of those options were higher than the average market price for shares for the period ended 30 June 2021.

## 8. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2021, the Group made additions to construction in progress of RMB3,724,000 (six months ended 30 June 2020: RMB4,403,000) and acquired other property, plant and equipment of RMB23,297,000 (six months ended 30 June 2020: RMB30,367,000). During the six months ended 30 June 2021, the Group also disposed of certain property, plant and equipment with carrying amount of RMB77,424,000 (six months ended 30 June 2020: RMB23,169,000) at net consideration of RMB69,187,000 (six months ended 30 June 2020: RMB26,119,000), resulting in a loss on disposal of RMB8,237,000 (six months ended 30 June 2020: gain on disposal of RMB2,950,000).

## 9. TRADE RECEIVABLES/TRADE RECEIVABLES BACKED BY BANK BILLS

	<b>30.6.2021</b> <i>RMB'000</i> (Unaudited)	31.12.2020 <i>RMB'000</i> (Audited)
Trade receivables	<b>411,591</b>	321,621
Less: Allowance for expected credit loss ("ECL")	<b>(10,354)</b>	(9,829)
	<b>401,237</b>	311,792
Trade receivables backed by bank bills	<b>371,688</b>	449,983
Less: Allowance for ECL	<b>(1,115)</b>	(1,115)
	<b>370,573</b>	448,868
	<b>771,810</b>	760,660

The Group allows credit periods normally ranging from six months to one year to its trade customers. The following is an aged analysis of the trade receivables and trade receivables backed by bank bills, net of allowance for ECL, presented based on the invoice date at the end of the reporting period, which approximated the respective revenue recognition dates.

	<b>30.6.2021</b> <b>RMB'000</b> <b>(Unaudited)</b>	31.12.2020 <b>RMB'000</b> <b>(Audited)</b>
Within 6 months	<b>677,170</b>	708,332
Over 6 months but less than 1 year	<b>80,020</b>	42,134
Over 1 year but less than 2 years	<b>13,413</b>	9,852
More than 2 years	<b>1,207</b>	342
	<b>771,810</b>	<b>760,660</b>

As at 30 June 2021, total bills received with carrying amount to RMB370,573,000 (31 December 2020: RMB448,868,000) are held by the Group for future settlement of trade receivables. All bills received by the Group are with a maturity period of less than one year.

#### 10. IMPAIRMENT LOSSES ON FINANCIAL ASSETS UNDER EXPECTED CREDIT LOSS MODEL, NET OF REVERSAL

	<b>Six months ended 30 June</b>	
	<b>2021</b> <b>RMB'000</b> <b>(Unaudited)</b>	2020 <b>RMB'000</b> <b>(Unaudited)</b>
Impairment losses on trade receivables	<b>525</b>	3,487

The basis of determining the inputs and assumptions and the estimation techniques used in the condensed consolidation financial statements for the six months ended 30 June 2021 are the same as those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2020.

#### 11. TRADE PAYABLES

	<b>30.6.2021</b> <b>RMB'000</b> <b>(Unaudited)</b>	31.12.2020 <b>RMB'000</b> <b>(Audited)</b>
Trade payables	<b>146,033</b>	164,377

An aged analysis of the Group's trade payables at the end of the reporting period is as follows:

	<b>30.6.2021</b> <b>RMB'000</b> <b>(Unaudited)</b>	31.12.2020 <b>RMB'000</b> <b>(Audited)</b>
Within 6 months	<b>134,679</b>	158,903
Over 6 months but less than 1 year	<b>1,905</b>	1,117
Over 1 year but less than 2 years	<b>624</b>	1,607
Over 2 years but less than 3 years	<b>6,810</b>	989
Over 3 years	<b>2,015</b>	1,761
	<b>146,033</b>	<b>164,377</b>

The average credit period taken for trade purchases ranges from two months to six months.

## 12. BANK BORROWINGS

	<b>30.6.2021</b> <b>RMB'000</b> <b>(Unaudited)</b>	31.12.2020 <b>RMB'000</b> <b>(Audited)</b>
Bank loans, unsecured	-	70,000
Loans related to bills discounted with recourse	-	299,319
	<b>-</b>	<b>369,319</b>

As at 31 December 2020, the bank loans of RMB70,000,000 were unsecured and repayable within one year and carried a fixed interest rate at 2.05% per annum.

As at 31 December 2020, the loans related to bills discounted with recourse of RMB299,319,000 were related to intercompany bills discounted, pledged by bank deposits and repayable within one year and carried a fixed interest rate at 2.72% per annum.



### **13. SHARE-BASED PAYMENT TRANSACTIONS**

#### **Share option scheme**

The Company has share option scheme which were adopted on 10 November 2004 and 29 May 2015. During the period, no share options were granted under the share option scheme of the Company.

#### **Share award scheme**

On 26 March 2018, the Company adopted the share award scheme (“the Scheme”) with objectives to recognise the contributions by certain employees and give incentives thereto in order to motivate them for the continual operation and development of the Group; and to attract suitable personnel for further development of the Group. The Scheme does not constitute a share option scheme or an arrangement analogous to a share option scheme for the purpose of Chapter 17 of the Listing Rules. Unless terminated earlier by the Board pursuant to the Scheme, the Scheme shall be valid and effective for a period of ten years commencing on the adoption date.

Pursuant to the Scheme, the Board may, from time to time, at its absolute discretion cause to be paid to the trustee sums of money from the Company’s resources for the purchase of shares to be held on trust in accordance with the Scheme and the trust deed. Such sums of money shall be applied towards the purchase of the specific number of shares from the open market according to the written instructions of the Board. The Board shall not make any further award which will result in the number of shares awarded by the Board under the Scheme exceeding 10% of the issued share capital of the Company as at the adoption date. The maximum aggregate number of the awarded shares which may be awarded to a selected employee under the Scheme shall not exceed 1% of the issued share capital of the Company as at the adoption date.

During the six months ended 30 June 2021, 800,000 shares were disposed of by the trustee to the market at an average price of approximately HK\$5.50 (equivalent to RMB4.58) per share. The proceeds from disposal of those shares amounted to HK\$4,403,000 (equivalent to RMB3,663,000). The difference of HK\$2,885,000 (equivalent to RMB2,400,000) between the cost of the shares and the proceeds was credited to accumulated profits. During the six months ended 30 June 2020, 7,032,000 shares were purchased by the trustee from the market at an average price of approximately HK\$5.70 (equivalent to RMB5.18) per share, with an aggregate amount of HK\$40,080,000 (equivalent to RMB36,437,000). No shares were granted to eligible employees pursuant to the share award scheme. At the end of the reporting period, there are 71,600,000 (31 December 2020: 72,400,000) shares held by the trustee.

#### 14. RELATED PARTY DISCLOSURES

Other than as disclosed elsewhere in the condensed consolidated financial statements, the Group has following transactions and balances with related parties:

Name of related parties	Nature of transactions	Six months ended 30 June	
		2021 RMB'000 (Unaudited)	2020 RMB'000 (Unaudited)
Shineway Medical Science & Technology Co., Ltd. ("Shineway Medical")	Interest expenses on lease liabilities	329	20
	Service fee	4,918	5,417
Shineway (Sanhe) Property Development Limited ("Shineway Sanhe")	Interest expenses on lease liabilities	79	26
	Service fee	1,205	1,273
Kang Yue Hotel Co., Ltd. ("Kang Yue Hotel")	Interest expenses on lease liabilities	90	25
	Hotel service fee	112	214
Shijiazhuang Municipal Luancheng County Shineway Training School ("Shineway Training School")	Service fee	201	936
Name of related parties	Nature of balances	30.6.2021 RMB'000 (Unaudited)	31.12.2020 RMB'000 (Audited)
Shineway Medical	Lease liabilities	11,652	13,815
Shineway Sanhe	Lease liabilities	2,806	3,326
Kang Yue Hotel	Lease liabilities	3,198	3,792

Shineway Medical, Shineway Sanhe, Kang Yue Hotel and Shineway Training School, all of which are ultimately controlled by the controlling shareholder of the Company.

## Compensation of key management personnel

Key management personnel is deemed to be the members of the Board of the Company which has responsibility for planning, directing and controlling the activities of the Group. Details of the remuneration paid to them during the period were as follows:

	Six months ended 30 June	
	2021	2020
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Short-term benefits	6,048	5,011
Post-employment benefits	30	33
Share-based payments expense	34	95
	<u>6,112</u>	<u>5,139</u>

## 15. CAPITAL COMMITMENTS

	30.6.2021	31.12.2020
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Audited)
Capital expenditure in respect of acquisition of property, plant and equipment contracted for but not provided in the condensed consolidated financial statements	<u>125,796</u>	<u>147,191</u>

## **OTHER INFORMATION**

### **CLOSURE OF SHARE TRANSFER REGISTRATION**

The register of members of the Company will be closed from 15 September 2021 to 16 September 2021 (both days inclusive). In order to qualify for the interim dividend for the six months ended 30 June 2021, all transfer documents accompanied by the relevant share certificates, must be lodged with the Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-16, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, not later than 4:30 p.m. on 14 September 2021.

### **PURCHASE, SALE OR REDEMPTION OF SECURITIES**

During the six months ended 30 June 2021, the Company or its subsidiaries did not purchase, sell or redeem any securities of the Company.

### **COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE**

The Company has complied with the code provisions set out in the Corporate Governance Code (the "Code") contained in Appendix 14 to the Listing Rules during the six months ended 30 June 2021, except for code provision A.2.1 as described below.

Code provision A.2.1 of the Code stipulates that the roles of chairman of the Board (the "Chairman") and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the Chairman and chief executive should be clearly established and set out in writing. The Company does not use the title "Chief Executive". The duty of the chief executive has been assumed by the president of the Company (the "President").

Mr. Li Zhenjiang has been both the Chairman and President. His responsibilities are clearly set out in writing and approved by the Board. Given the Group's current stage of development, the Board considers that vesting the roles of Chairman and President in the same person facilitates the execution of the Group's business strategies and maximizes effectiveness of its operations. The Board shall nevertheless review the relevant structure from time to time and shall consider any appropriate adjustments should new circumstances arise.

## **COMPLIANCE WITH THE MODEL CODE**

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (“Model Code”) as set out in Appendix 10 to the Listing Rules as the code of conduct regarding securities transactions by directors of the Company on terms no less exacting than the required standard set out in the Model Code. The prohibitions on securities dealing and disclosure requirements in the Model Code apply to specified individuals including the Group’s senior management and also persons who are privy to price sensitive information of the Group. Having made specific enquiry, all directors of the Company confirmed that they had complied with the required standard set out in the Model Code regarding securities transactions of the directors for the six months ended 30 June 2021.

## **AUDIT COMMITTEE**

The audit committee of the Company has reviewed with management and external auditors the accounting principles and policies adopted by the Group and the unaudited consolidated results of the Group for the six months ended 30 June 2021.

## **INTERIM REPORT**

The interim report of 2021 will be despatched to the shareholders of the Company and published on the website of The Stock Exchange of Hong Kong Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company’s website ([www.shineway.com.hk](http://www.shineway.com.hk)) in due course.

We are delighted by the trust and support of our shareholders and those who care about the Company. On behalf of the Board, we would like to take this opportunity to thank all of you, as well as our employees who made tremendous efforts.

By order of the Board  
**China Shineway Pharmaceutical Group Limited**  
**Li Zhenjiang**  
*Chairman*

Hong Kong, 31 August 2021

*As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Cheung Chun Yue Anthony.*